(NASDAQ: RYTM) Rhythm Pharmaceuticals's forecast annual revenue growth rate of 48.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.71%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Rhythm Pharmaceuticals's revenue in 2025 is $156,287,000.On average, 12 Wall Street analysts forecast RYTM's revenue for 2025 to be $12,327,568,890, with the lowest RYTM revenue forecast at $11,574,365,058, and the highest RYTM revenue forecast at $12,953,246,147. On average, 12 Wall Street analysts forecast RYTM's revenue for 2026 to be $19,742,973,529, with the lowest RYTM revenue forecast at $16,046,429,785, and the highest RYTM revenue forecast at $24,384,808,009.
In 2027, RYTM is forecast to generate $35,716,673,314 in revenue, with the lowest revenue forecast at $30,436,342,500 and the highest revenue forecast at $45,540,271,193.